Neofordex (dexamethasone acetate high-dose) / CTRS Laboratories, Zaphyr Pharma - LARVOL DELTA

SABLe: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (clinicaltrials.gov) - P2 | N=50 | Active, not recruiting | Sponsor: Ida Bruun Kristensen | Trial primary completion date: Jun 2024 ➔ Aug 2025

Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov) - P2 | N=96 | Suspended | Sponsor: Hackensack Meridian Health | Trial completion date: Jan 2025 ➔ Jan 2026 | Recruiting ➔ Suspended | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Trial suspension • Hematological Malignancies • Multiple Myeloma • Oncology

FREEDOM: Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone (clinicaltrials.gov) - P3 | N=318 | Recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris | Not yet recruiting ➔ Recruiting

Enrollment open • Head-to-Head • Metastases • Hematological Malignancies • Multiple Myeloma • Oncology

FREEDOM: Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without Dexamethasone (clinicaltrials.gov) - P3 | N=318 | Not yet recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris

Head-to-Head • Metastases • New P3 trial • Hematological Malignancies • Multiple Myeloma • Oncology

SABLe: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (clinicaltrials.gov) - P2 | N=50 | Active, not recruiting | Sponsor: Ida Bruun Kristensen | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov) - P2 | N=96 | Recruiting | Sponsor: Hackensack Meridian Health | Phase classification: P2b ➔ P2 | Trial completion date: Jan 2024 ➔ Jan 2025 | Trial primary completion date: Jan 2024 ➔ Jan 2025

Combination therapy • Phase classification • Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

SABLe: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Ida Bruun Kristensen | N=100 ➔ 50

Enrollment change • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

IVIORDEX: IgIV Plus Prednisone vs High-dose Dexamethasone for ITP (clinicaltrials.gov) - P3 | N=272 | Recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris | Not yet recruiting ➔ Recruiting | Trial completion date: Jul 2026 ➔ Oct 2026 | Trial primary completion date: Jan 2025 ➔ Apr 2025

Enrollment open • Trial completion date • Trial primary completion date • Congestive Heart Failure • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov) - P2b | N=96 | Recruiting | Sponsor: Hackensack Meridian Health | Trial primary completion date: Jan 2023 ➔ Jan 2024

Combination therapy • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov) - P2b | N=96 | Recruiting | Sponsor: Hackensack Meridian Health | Trial completion date: Jan 2023 ➔ Jan 2024

Combination therapy • Trial completion date • Hematological Malignancies • Multiple Myeloma • Oncology

IVIORDEX: IgIV Plus Prednisone vs High-dose Dexamethasone for ITP (clinicaltrials.gov) - P3; N=272; Not yet recruiting; Sponsor: Assistance Publique - Hôpitaux de Paris; Trial completion date: Apr 2025 ➔ Jul 2026; Initiation date: Oct 2021 ➔ Jan 2022; Trial primary completion date: Oct 2024 ➔ Jan 2025

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Congestive Heart Failure • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura

A randomized phase 3 study of Teclistamab in combination with daratumumab verses an Investigators choice of Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Velcade, Dexamethasone in Relapsed or Refractory Multiple Myeloma (clinicaltrialsregister.eu) - P3; N=560; Ongoing; Sponsor: Janssen-Cilag International NV

Clinical • Combination therapy • New P3 trial • Hematological Malignancies • Multiple Myeloma • Oncology

SABLe: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (clinicaltrials.gov) - P2; N=100; Recruiting; Sponsor: Ida Bruun Kristensen; Not yet recruiting ➔ Recruiting; Initiation date: Apr 2021 ➔ Aug 2021

Clinical • Enrollment open • Trial initiation date • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

IVIORDEX: IgIV Plus Prednisone vs High-dose Dexamethasone for ITP (clinicaltrials.gov) - P3; N=272; Not yet recruiting; Sponsor: Assistance Publique - Hôpitaux de Paris

Clinical • New P3 trial • Congestive Heart Failure • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura

SABLe: Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (clinicaltrials.gov) - P2; N=100; Not yet recruiting; Sponsor: Ida Bruun Kristensen

Clinical • New P2 trial • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma (clinicaltrials.gov) - P2b; N=96; Not yet recruiting; Sponsor: Hackensack Meridian Health

Clinical • Combination therapy • New P2b trial • Hematological Malignancies • Multiple Myeloma • Oncology